Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma
Brief Summary: This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in subjects with refractory or relapsed CD20+ B-cell lymphoma.


Options:
A: Arm Label: 1A/T cell Arm (closed); Type: EXPERIMENTAL; Interventions: Procedure: Allogeneic stem cell transplant, Biological: Anti-CD19-chimeric-antigen-receptor-transduced T cells | Arm Label: 1B/T memory stem cell arm; Type: EXPERIMENTAL; Interventions: Procedure: Allogeneic stem cell transplant, Biological: Anti-CD19-chimeric-antigen-receptor-transduced T cells | Arm Label: 2/Donor arm; Type: OTHER; Interventions: Procedure: Leukapheresis | Intervention Type: PROCEDURE; Name: Allogeneic stem cell transplant; Assigned to Arm(s): 1A/T cell Arm (closed), 1B/T memory stem cell arm | Intervention Type: BIOLOGICAL; Name: Anti-CD19-chimeric-antigen-receptor-transduced T cells; Assigned to Arm(s): 1A/T cell Arm (closed), 1B/T memory stem cell arm | Intervention Type: PROCEDURE; Name: Leukapheresis; Assigned to Arm(s): 2/Donor arm
B: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Biological: CD19 CAR T cells | Intervention Type: BIOLOGICAL; Name: CD19 CAR T cells; Assigned to Arm(s): Single Arm
C: Arm Label: Treatment (cellular adoptive immunotherapy following PBSCT); Type: EXPERIMENTAL; Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation, Biological: Filgrastim, Biological: Genetically Engineered Lymphocyte Therapy, Other: Laboratory Biomarker Analysis, Procedure: Peripheral Blood Stem Cell Transplantation, Drug: Plerixafor, Biological: Rituximab | Intervention Type: PROCEDURE; Name: Autologous Hematopoietic Stem Cell Transplantation; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: BIOLOGICAL; Name: Filgrastim; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: BIOLOGICAL; Name: Genetically Engineered Lymphocyte Therapy; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: PROCEDURE; Name: Peripheral Blood Stem Cell Transplantation; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: DRUG; Name: Plerixafor; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT) | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Treatment (cellular adoptive immunotherapy following PBSCT)
D: Arm Label: ACTR087, in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR087, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR087; Assigned to Arm(s): ACTR087, in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR087, in combination with rituximab

Answer: D